Abstract:Rheumatoid arthritis (RA) is a systemic, autoimmune disease that affects joints and extra-articular structures. In the last decade, the management of this chronic disease has dramatically changed with the introduction of several targeted mechanisms of action, such as tumor necrosis factor-α inhibition, T-cell costimulation inhibition, B-cell depletion, interleukin-6 blockade, and Janus kinase inhibition. Beyond its well-known hematopoietic role on the proliferation and differentiation of myeloid cells, granulocyte-monocyte colony-stimulating factor (GM-CSF) is a proinflammatory mediator acting as a cytokine, with a proven pathogenetic role in autoimmune disorders such as RA. In vitro studies clearly demonstrated the effect of GM-CSF in the communication between resident tissue cells and activated macrophages at chronic inflammation sites, and confirmed the elevation of GM-CSF levels in inflamed synovial tissue of RA subjects compared with healthy controls. Moreover, a pivotal role of GM-CSF in the perception of pain has been clearly confirmed. Therefore, blockade of the GM-CSF pathway by monoclonal antibodies directed against the cytokine itself or its receptor has been investigated in refractory RA patients. Overall, the safety profile of GM-CSF inhibitors seems to be very favorable, with a particularly low incidence of infectious complications. The efficacy of this new mechanism of action is comparable with main competitors, even though the response rates reported in phase II randomized controlled trials (RCTs) appear to be numerically lower than the response rates observed with other biological disease-modifying antirheumatic drugs already licensed for RA. Mainly because of this reason, nowadays the development program of most GM-CSF blockers for RA has been discontinued, with the exception of otilimab, which is under evaluation in two phase III RCTs with a head-to head non-inferiority design against tofacitinib. These studies will likely be useful for better defining the potential role of GM-CSF inhibition in the therapeutic algorithm of RA. On the other hand, the potential role of GM-CSF blockade in the treatment of other rheumatic diseases is now under investigation. Phase II trials are ongoing with the aim of evaluating mavrilimumab for the treatment of giant cell arteritis, and namilumab for the treatment of spondyloarthritis. Moreover, GM-CSF inhibitors have been tested in osteoarthritis and diffuse subtype of systemic sclerosis. This review aims to describe in detail the available evidence on the GM-CSF blocking pathway in RA management, paving the way to a possible alternative treatment for RA patients. Novel insights regarding the potential use of GM-CSF blockers for alternative indications will be also addressed.

Anti-colony-stimulating factor therapies for inflammatory and autoimmune diseases

GM-CSF in inflammation

Targeting CSF-1R represents an effective strategy in modulating inflammatory diseases

Targeting Granulocyte-Monocyte Colony-Stimulating Factor Signaling in Rheumatoid Arthritis: Future Prospects

Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy

Roles of GM-CSF in the Pathogenesis of Autoimmune Diseases: An Update

Targeting the GM-CSF Receptor for the Treatment of CNS Autoimmunity.

Colony-stimulating factor (CSF) 1 receptor blockade reduces inflammation in human and murine models of rheumatoid arthritis

Granulocyte–macrophage colony-stimulating factor: not just another haematopoietic growth factor

Function of CSF1 and IL34 in Macrophage Homeostasis, Inflammation, and Cancer.

GM-CSF-Dependent Inflammatory Pathways

The multifaceted effects of granulocyte colony-stimulating factor in immunomodulation and potential roles in intestinal immune homeostasis.

Myeloid Colony-Stimulating Factors As Regulators of Macrophage Polarization.

Inhibition of colony stimulating factor-1 receptor (CSF-1R) as a potential therapeutic strategy for neurodegenerative diseases: opportunities and challenges

Effect of granulocyte colony stimulating factor in immunomodulation and role in intestinal immune homeostasis

CSF-1 Maintains Pathogenic but Not Homeostatic Myeloid Cells in the Central Nervous System During Autoimmune Neuroinflammation

Granulocyte-macrophage colony-stimulating factor negatively regulates early IL-10-mediated responses

Evaluation of the effect of GM-CSF blocking on the phenotype and function of human monocytes

Myeloid-derived Suppressor Cells and Multiple Sclerosis

GM-CSF Primes Proinflammatory Monocyte Responses in Ankylosing Spondylitis

The mechanism of GM-CSF inhibition by human GM-CSF auto-antibodies suggests novel therapeutic opportunities